Semble funding, valuation and investors

Overview

Semble is a London-based healthtech company founded in 2016 by Mikael Landau and Christoph Lippuner. Its cloud platform combines electronic health records, scheduling, billing, patient communications, e-prescriptions, and telehealth for private outpatient clinics across 80+ specialties. Semble Connect integrates with 1,200+ external tools (CRM, labs, diagnostics, HR) and serves 1,700+ healthcare businesses used daily by 16,000+ clinicians. In June 2026 Semble raised £30 million Series C led by Revaia with new investor Partech and returning Mercia Ventures and Octopus Ventures, bringing total funding to approximately £57 million. The company operates primarily in the UK and France and is investing in AI-powered care orchestration.

Why Semble is interesting

Semble passed 10M patients on its platform—roughly one in six people in the UK touched a Semble-powered clinician—then raised £30M Series C to become the "system of action" for outpatient care orchestration, not another digital filing cabinet.

Product & use cases

Semble unifies clinical workflows (consultations, records, e-prescribing) with practice operations (booking, invoicing, reminders, payments) in one platform. Enterprise customers use Semble Connect and APIs to automate finance, marketing, and diagnostics integrations without replacing core clinical software.

• Solo GPs and consultants replacing legacy practice-management systems
• Multi-site private clinic groups standardizing scheduling and billing across locations
• Mental health, physio, and specialty practices needing telehealth and patient portals
• Large healthcare enterprises orchestrating care journeys across UK and France

Key facts

• Series C (Jun 2026): £30M led by Revaia; Partech new; Mercia and Octopus return
• 10M+ patients received care via Semble clinicians; 1,700+ healthcare businesses
• 1,200+ integrations via Semble Connect—positioned as Europe's most connected private-health platform
• 16,000+ daily clinical users across 80+ specialties
• Total funding ~£57M after nearly doubling since £11.5M Series B (Oct 2024)
• Subscription pricing from ~£119/user/month per public listings

Funding history (newest first)

Competitive landscape

Edge: Interoperability depth—1,200+ tool connections—and clinical + operational unity versus legacy EHRs that store records without orchestrating the full patient journey.

European private healthcare IT is fragmented; winners need switching costs via integrations and multi-site deployments. Semble's Series C funds expansion among large groups and AI orchestration—competing on connected workflows, not feature checklists alone.

• EMIS / legacy UK EHR vendors incumbent

  Established NHS and private systems; Semble targets modern cloud-native private outpatient providers.

• Hint Health direct

  Direct-primary-care practice software; overlapping private-clinic audience.

• Modernizing Medicine direct

  Specialty-specific cloud EHR; Semble emphasizes cross-specialty platform breadth in Europe.

• Doctolib adjacent

  Booking and practice tools in France; overlaps on scheduling though Semble is broader PM+EHR.

Notable stories

• Semble reported that 10 million UK patients—about one in six—received care from a clinician using its platform at Series C announcement (Semble blog, June 2026).
• Revaia partner Morgan Kessous called Semble the "system of action for modern healthcare," not just storage—a framing the company uses against legacy EHR positioning (Semble press release).

Industries

Market / IPO context

Related funding articles

Venture Capital Tracker pieces that cover Semble's financing or category context.

• Semble's £30M Series C: Modern Software for Healthcare Providers